Table 1 Accrual to whole brain radiotherapy trials
Trial | Design | Histology and no. of BMs | Appropriate NCF testing | Actual recruitment (patients/years) | Average no. of patients accrued per year | Total number of melanoma patients (%) |
|---|---|---|---|---|---|---|
Patchell et al. [8] | WBRT vs. OBS | All solid tumours (mainly lung) Sol BM post- surgery | No | 96/8 years | 12 | 2 (2%) |
Aoyama et al. [9] | SR vs. WBRT + SRS | All solid tumours (mainly lung) 1–4 BMs | No | 132/4 years | 33 | Unknown |
Kocher et al. [10] | SR vs. SR + WBRT | All solid tumours (mainly lung) 1–3 BMs | No | 359/11 years | 33 | 18 (5%) |
Chang et al. [11] | SR vs. WBRT + SR | All solid tumours (mainly lung) 1–3 BMs | Yes | 58/6 years | 10 Early closure | 7 patients (12%) |
Roos et al. [12]* | WBRT vs. OBS | All solid tumours sol BM post-SR/surgery | No | 19/3 years | 6 | 3 (16%) |
This study | WBRT vs. observation | Melanoma only 1–3 BMs post-SR/surgery | Yes | 54/2 years | 27 | 54 (100%) |